US representatives Kurt Schrader and Adam Kinzinger recently introduced the bipartisan Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, garnering support from the Association for Accessible medicines and a group of organizations representing patients, employers, taxpayers, providers, communities of color and consumer groups.
The AAM noted that “under Medicare Part B, health care providers are reimbursed the average sales price of the brand-name...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?